| Similar Articles |
|---|
 |
The Motley Fool
May 14, 2007
Brian Lawler |
Sour Results for Nektar Nektar Therapeutics announces its first-quarter financial results and plans for the future. Investors, take note.   |
The Motley Fool
February 29, 2008
Brian Lawler |
Nektar Squeezing Along Nektar Therapeutics finishes a topsy-turvy 2007, and gives some good guidance for upcoming year. |
The Motley Fool
November 3, 2006
Brian Lawler |
Nektar Worth Waiting For? Investors might be getting impatient, but the new insulin the company makes is special. |
The Motley Fool
November 13, 2007
Brian Lawler |
Nektar's New Old Drug Pfizer returns its non-selling inhalable insulin experiment Exubera to Nektar Therapeutics today, along with $135 million in cash. |
The Motley Fool
August 7, 2007
Brian Lawler |
Nektar Makes a Deal Nektar Therapeutics signs a deal with Bayer AG in an effort to move itself closer to profitability. In return, Bayer gets a co-promotion profit-sharing deal in the U.S., and commercialization rights elsewhere. |
The Motley Fool
April 10, 2008
Brian Lawler |
Nektar Can't Squeeze Nectar From This Drug Nektar Therapeutics announced that it was putting its inhaled insulin drug, Exubera, to rest. Investors, take note. |
The Motley Fool
May 22, 2006
Stephen D. Simpson |
Nektar Full of Potential, Risk Can inhaled insulin sales live up to investors' expectations at Nektar Therapeutics? |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
December 1, 2004
Brian Gorman |
Rational Exuberance Nektar received a positive boost from Pfizer's announcement that it will seek approval for Exubera, an inhaled form of insulin. The drug delivery specialist's stock promptly surged, closing up 23% yesterday. |
The Motley Fool
October 19, 2007
Brian Lawler |
The Exubera Winner In its third-quarter earnings report, Pfizer announces it is surrendering the rights to market inhalable-insulin treatment Exubera to developer Nektar Therapeutics. Investors, take note. |
The Motley Fool
August 6, 2007
Brian Lawler |
Unhappy Delays for MannKind Two delays for the inhalable insulin developer cause the stock to drop. |
The Motley Fool
September 22, 2009
Brian Orelli |
Nektar Tastes Sweet Nektar is getting an up-front payment of $125 million and AstraZeneca is taking over development of two of its compounds. |
The Motley Fool
January 16, 2008
Brian Lawler |
Another Inhalable Insulin Bites the Dust Novo Nordisk discontinues development of its troubled diabetes treatment and settles its patent infringement lawsuit against Pfizer. Investors, take note. |
The Motley Fool
November 15, 2007
Brian Orelli |
Slowing the Cash Burn Bloody Nose Nastech plans to cut costs following Proctor& Gamble's drop of their osteoporosis drug. Investors, take note. |
The Motley Fool
May 27, 2011
Brian Orelli |
What Kind of Phase 2 Drug Can You Get for $5 Million? Cell Therapeutics issues a press release saying the company has identified a potential acquisition opportunity that is a phase II drug candidate. |
The Motley Fool
September 9, 2005
Stephen D. Simpson |
Diabetics Breathing Easier Investors in Pfizer, Sanofi-Aventis, and Nektar Therapeutics might be breathing a bit easier today. The FDA's expert panel recommended approval for Exubera. |
The Motley Fool
May 6, 2008
Brian Lawler |
MannKind Moves Ahead The pharmaceutical awaits pivotal data on its lead drug Technosphere. |
The Motley Fool
January 13, 2006
Stephen D. Simpson |
Pfizer Pays Sanofi to Go Away Two large pharmaceutical companies settle a dispute over inhaled insulin, and $1.3 billion changes hands. Investors, take note. |
The Motley Fool
November 5, 2007
Brian Lawler |
Follow the Trend With Novo Nordisk The future is bright for Danish drugmaker Novo Nordisk. The worldwide leader in diabetes treatments turns in another good quarter. |
The Motley Fool
December 5, 2008
Brian Orelli |
Be Kind to MannKind MannKind has good data on its inhaled insulin drug, but will the FDA approve of it and will diabetics buy it? |
The Motley Fool
September 19, 2006
Brian Lawler |
A Long Wait for MannKind The company's inhaled insulin might not reach the market for several years, if it does, but it's a big market. Investors, take note. |
The Motley Fool
March 2, 2005
Bill Mann |
How Hated Is Pfizer? The FDA accepts Pfizer's application for what could be a monster drug, and the market yawns. |
The Motley Fool
December 31, 2009
Brian Orelli |
2010 FDA Decisions to Watch It's a pivotal year for these drugmakers. |
InternetNews
October 18, 2004
Allen Bernard |
Tech Job Cuts Leap 60% Announced job cuts in the technology sector soared 60% in the third quarter to 54,701, the highest figure since the fourth quarter of 2003 (82,328). |
The Motley Fool
June 11, 2007
Brian Lawler |
More Air for Alkermes The biopharmaceutical drug delivery expert brings another drug into clinic stage testing. Investors, take note. |
The Motley Fool
July 30, 2010
Brian Orelli |
MannKind: Strengths, Weaknesses, Opportunities, Threats It's all about the inhaled insulin. |
The Motley Fool
March 25, 2011
Selena Maranjian |
Make Money in Pharmaceuticals the Easy Way There's no need to guess which pharmaceutical company will perform best with the SPDR S&P Pharmaceuticals ETF. |
The Motley Fool
February 29, 2008
Brian Orelli |
2007 Pharma Roundup How did big pharma do in 2007? With the drug sector earnings season winding down, now seems like a good time to take a look at how they fared and, more importantly, where they're headed. |
The Motley Fool
September 28, 2010
Brian Orelli |
Don't Get Stuck! Invest in Needle-Free Drugs Here's how to make some money off society's general disdain for needles through next-generation drugs. |
The Motley Fool
June 26, 2009
Brian Orelli |
Rumors and Safety Issues -- One Bad Combination There are rumors floating around that a study will show that use of Sanofi's insulin product, Lantus, has an increased risk of cancer. |
The Motley Fool
October 22, 2007
Brian Lawler |
Not Another Pfizer Pfailure As Pfizer's top execs have said before, losing patent protections on many of its top products around the same time makes for a difficult operating environment. Pfizer's third-quarter results showed just how difficult those losses were. |
The Motley Fool
July 20, 2006
Stephen D. Simpson |
Pfizer's Big Plans Between the launch of inhaled insulin and spending $34 billion, Pfizer has a lot on its plate. Investors, take note. |
The Motley Fool
June 19, 2009
Robert Steyer |
MannKind Needs More Leaps Getting FDA approval for its inhaled-insulin product is only one hurdle for this start-up pharmaceutical. |
